Accueil   Diary - News   All news Advanced BioDesign publishes its study in non-small cell lung cancer (NSCLC) in Oncogene

Advanced BioDesign publishes its study in non-small cell lung cancer (NSCLC) in Oncogene


Study shows for first time benefit of its active compound DIMATE
in overcoming drug resistance in NSCLC



Lyon, France, May 12, 2020 – Advanced BioDesign, dedicated to developing novel therapies against resistant cancers, today announces promising results using its dual inhibitor DIMATE against an original therapeutic target, the ALDH enzymes family, in pulmonary cancer. The results, recently published in Oncogene, demonstrate that in lung cancer xenografts with high to moderate cisplatin resistance, a combination treatment with DIMATE promotes strong synergistic responses with tumor regression.


In support of these findings, the study highlights a new mechanism of action associated with the therapeutic target: the ALDH enzymes, notably ALDH1A3 and ALDH3A1. High expression of these enzymes confers an aggressive, chemoresistant behavior in non-small cell lung cancer (NSCLC) and reduces patient survival. This strongly suggests that ALDH1A3 and ALDH3A1 make cancer cells resistant to chemotherapy by disposing of their toxic compounds induced by chemotherapy, such as aldehydes and reactive oxygen species (ROS). A combination of DIMATE together with ROS-inducing agents, such as cisplatin, triggers a potent anti-tumor response at lower doses of chemotherapy, which also results in fewer side-effects.




Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree